High Levels of Complement Activating Enzyme MASP-2 Are Associated With the Risk of Future Incident Venous Thromboembolism
Background: Experimental studies have shown that the complement activating enzyme MASP-2 (mannose-binding lectin associated serine protease 2) exhibits a thrombin-like activity and that inhibition of MASP-2 protects against thrombosis. In this study, we investigated whether plasma MASP-2 levels were...
Published in: | Arteriosclerosis, Thrombosis, and Vascular Biology |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Ovid Technologies (Wolters Kluwer Health)
2022
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1161/atvbaha.122.317746 https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.122.317746 |
id |
crovidcr:10.1161/atvbaha.122.317746 |
---|---|
record_format |
openpolar |
spelling |
crovidcr:10.1161/atvbaha.122.317746 2024-02-04T10:05:01+01:00 High Levels of Complement Activating Enzyme MASP-2 Are Associated With the Risk of Future Incident Venous Thromboembolism Damoah, Christabel Esi Snir, Omri Hindberg, Kristian Garred, Peter Ludviksen, Judith K. Brækkan, Sigrid K. Morelli, Vânia M. Mollnes, Tom Eirik Hansen, John-Bjarne 2022 http://dx.doi.org/10.1161/atvbaha.122.317746 https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.122.317746 en eng Ovid Technologies (Wolters Kluwer Health) Arteriosclerosis, Thrombosis, and Vascular Biology volume 42, issue 9, page 1186-1197 ISSN 1079-5642 1524-4636 Cardiology and Cardiovascular Medicine journal-article 2022 crovidcr https://doi.org/10.1161/atvbaha.122.317746 2024-01-05T10:21:15Z Background: Experimental studies have shown that the complement activating enzyme MASP-2 (mannose-binding lectin associated serine protease 2) exhibits a thrombin-like activity and that inhibition of MASP-2 protects against thrombosis. In this study, we investigated whether plasma MASP-2 levels were associated with risk of future venous thromboembolism (VTE) and whether genetic variants linked to MASP-2 levels were associated with VTE risk. Methods: We conducted a population-based nested case-control study involving 410 VTE patients and 842 age- and sex-matched controls derived from the Norwegian Tromsø Study. Logistic regression was used to estimate odds ratios (ORs) of VTE across MASP-2 quartiles. Whole-exome sequencing and protein quantitative trait loci analyses were performed to assess genetic variants associated with MASP-2 levels. A 2-sample Mendelian randomization study, also including data from the INVENT consortium (International Network of Venous Thrombosis), was performed to assess causality. Results: Subjects with plasma MASP-2 in the highest quartile had a 48% higher OR of VTE (OR, 1.48 [95% CI, 1.06–2.06]) and 83% higher OR of deep vein thrombosis (OR, 1.83 [95% CI, 1.23–2.73]) compared with those with MASP-2 levels in the lowest quartile. The protein quantitative trait loci analysis revealed that 3 previously described gene variants, rs12711521 (minor allele frequency, 0.153), rs72550870 (minor allele frequency, 0.045; missense variants in the MASP2 gene), and rs2275527 (minor allele frequency, 0.220; exon variant in the adjacent MTOR gene) explained 39% of the variation of MASP-2 plasma concentration. The OR of VTE per 1 SD increase in genetically predicted MASP-2 was 1.03 ([95% CI, 1.01–1.05] P =0.0011). Conclusions: Our findings suggest that high plasma MASP-2 levels are causally associated with risk of future VTE. Article in Journal/Newspaper Tromsø Ovid (via Crossref) Tromsø Arteriosclerosis, Thrombosis, and Vascular Biology |
institution |
Open Polar |
collection |
Ovid (via Crossref) |
op_collection_id |
crovidcr |
language |
English |
topic |
Cardiology and Cardiovascular Medicine |
spellingShingle |
Cardiology and Cardiovascular Medicine Damoah, Christabel Esi Snir, Omri Hindberg, Kristian Garred, Peter Ludviksen, Judith K. Brækkan, Sigrid K. Morelli, Vânia M. Mollnes, Tom Eirik Hansen, John-Bjarne High Levels of Complement Activating Enzyme MASP-2 Are Associated With the Risk of Future Incident Venous Thromboembolism |
topic_facet |
Cardiology and Cardiovascular Medicine |
description |
Background: Experimental studies have shown that the complement activating enzyme MASP-2 (mannose-binding lectin associated serine protease 2) exhibits a thrombin-like activity and that inhibition of MASP-2 protects against thrombosis. In this study, we investigated whether plasma MASP-2 levels were associated with risk of future venous thromboembolism (VTE) and whether genetic variants linked to MASP-2 levels were associated with VTE risk. Methods: We conducted a population-based nested case-control study involving 410 VTE patients and 842 age- and sex-matched controls derived from the Norwegian Tromsø Study. Logistic regression was used to estimate odds ratios (ORs) of VTE across MASP-2 quartiles. Whole-exome sequencing and protein quantitative trait loci analyses were performed to assess genetic variants associated with MASP-2 levels. A 2-sample Mendelian randomization study, also including data from the INVENT consortium (International Network of Venous Thrombosis), was performed to assess causality. Results: Subjects with plasma MASP-2 in the highest quartile had a 48% higher OR of VTE (OR, 1.48 [95% CI, 1.06–2.06]) and 83% higher OR of deep vein thrombosis (OR, 1.83 [95% CI, 1.23–2.73]) compared with those with MASP-2 levels in the lowest quartile. The protein quantitative trait loci analysis revealed that 3 previously described gene variants, rs12711521 (minor allele frequency, 0.153), rs72550870 (minor allele frequency, 0.045; missense variants in the MASP2 gene), and rs2275527 (minor allele frequency, 0.220; exon variant in the adjacent MTOR gene) explained 39% of the variation of MASP-2 plasma concentration. The OR of VTE per 1 SD increase in genetically predicted MASP-2 was 1.03 ([95% CI, 1.01–1.05] P =0.0011). Conclusions: Our findings suggest that high plasma MASP-2 levels are causally associated with risk of future VTE. |
format |
Article in Journal/Newspaper |
author |
Damoah, Christabel Esi Snir, Omri Hindberg, Kristian Garred, Peter Ludviksen, Judith K. Brækkan, Sigrid K. Morelli, Vânia M. Mollnes, Tom Eirik Hansen, John-Bjarne |
author_facet |
Damoah, Christabel Esi Snir, Omri Hindberg, Kristian Garred, Peter Ludviksen, Judith K. Brækkan, Sigrid K. Morelli, Vânia M. Mollnes, Tom Eirik Hansen, John-Bjarne |
author_sort |
Damoah, Christabel Esi |
title |
High Levels of Complement Activating Enzyme MASP-2 Are Associated With the Risk of Future Incident Venous Thromboembolism |
title_short |
High Levels of Complement Activating Enzyme MASP-2 Are Associated With the Risk of Future Incident Venous Thromboembolism |
title_full |
High Levels of Complement Activating Enzyme MASP-2 Are Associated With the Risk of Future Incident Venous Thromboembolism |
title_fullStr |
High Levels of Complement Activating Enzyme MASP-2 Are Associated With the Risk of Future Incident Venous Thromboembolism |
title_full_unstemmed |
High Levels of Complement Activating Enzyme MASP-2 Are Associated With the Risk of Future Incident Venous Thromboembolism |
title_sort |
high levels of complement activating enzyme masp-2 are associated with the risk of future incident venous thromboembolism |
publisher |
Ovid Technologies (Wolters Kluwer Health) |
publishDate |
2022 |
url |
http://dx.doi.org/10.1161/atvbaha.122.317746 https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.122.317746 |
geographic |
Tromsø |
geographic_facet |
Tromsø |
genre |
Tromsø |
genre_facet |
Tromsø |
op_source |
Arteriosclerosis, Thrombosis, and Vascular Biology volume 42, issue 9, page 1186-1197 ISSN 1079-5642 1524-4636 |
op_doi |
https://doi.org/10.1161/atvbaha.122.317746 |
container_title |
Arteriosclerosis, Thrombosis, and Vascular Biology |
_version_ |
1789973885487153152 |